<p>6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients.  </p>

6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients.

<p>6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients. &nbsp;</p>

Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers.  The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Science

Medicine

Health & Fitness

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Share Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients

Sign up to save your podcasts

Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients

Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients